Abstract 1205P
Background
The probability of discovering mutation-based therapy through comprehensive genomic profiling (CGP) remains low. To enhance the effectiveness and efficiency of precision medicine, it is crucial to identify patients who are likely to benefit from CGP tests. This study aimed to identify characteristics of patients in which mutation-based treatments are discovered by CGP tests.
Methods
We retrospectively analyzed data from 60,655 patients registered in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, which covers 99.7% of cancer patients who have undergone CGP tests in Japan. We developed an eXtreme Gradient Boosting (XGBoost) machine learning model, and used clinical information as input to predict the likelihood of discovering mutation-based drugs through CGP tests. SHapley Additive exPlanations (SHAP) was employed to extract significant features contributing to the model prediction.
Results
The prediction model achieved an area under the receiver operating characteristic curve of 0.819 for the overall cancer population. Positive SHAP values were observed for patients with breast (mean SHAP in breast cancer patients: 1.66), lung (1.19), prostate (0.81), and colorectal (0.17) cancers, while negative SHAP values were associated with pancreatic (-2.40), brain (-1.37), and biliary tract (-0.44) cancers. Positive SHAP values were also associated with the presence of distant metastases and advanced age. Similar trends were observed in cancer type-specific prediction models. Distant metastasis was also associated with discovery of mutation-based therapy in the breast cancer-specific model, even after excluding liquid CGP data. In the adolescent and young adult (AYA) group, brain and bone tumors were associated with negative SHAP values.
Conclusions
Our analysis identified features that predict cases in which mutation-based treatments are discovered by CGP tests, both in the overall cancer population and within specific cancer types and the AYA group. Expedited CGP testing is recommended for patients who match the identified profile to facilitate early targeted therapy interventions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Watanabe, H. Kage: Financial Interests, Institutional, Research Funding: Konica Minolta. K. Oda: Financial Interests, Personal, Advisory Role: Chugai Pharma, Takeda, AstraZeneca/Merck, AstraZeneca, Konica Minolta; Financial Interests, Institutional, Research Funding: AstraZeneca/Merck, Konica Minolta. All other authors have declared no conflicts of interest.
Resources from the same session
1584P - Association of travel burden (TB) with colorectal cancer (CRC) outcomes in resource-limited settings (RLS)
Presenter: Saquib Banday
Session: Poster session 10
1585P - Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023)
Presenter: Giovanni Maria Iannantuono
Session: Poster session 10
1586P - Current status of breast cancer: A comparative analysis between developed and developing countries
Presenter: Ana Isabel Martin Quesada
Session: Poster session 10
1587P - As seen through Hollywood’s lens: Cancer in movies, 2010-2020
Presenter: David Benjamin
Session: Poster session 10
1588P - Interventions to improve Herpes Zoster (HZ) vaccination rate among cancer outpatients receiving systemic treatments: A single-center real-world experience
Presenter: Sara Di Bella
Session: Poster session 10
1589P - Ramping up phase I trial recruitment: Defining potential barriers and disparities
Presenter: Burak Aktas
Session: Poster session 10
1590P - Prevalence and impact on survival of presentation to the emergency room of cancer patients: A retrospective study on real-life data
Presenter: Sonia Priou
Session: Poster session 10
1591P - Development and economic trends in new anticancer therapies licensed in the UK from 2020 to 2024
Presenter: Geetin Majhail
Session: Poster session 10
1592P - Awareness and interest of oncology professionals in sex and gender differences in cancer risk and outcome: Analysis of an ESMO Gender Medicine Task Force survey
Presenter: Berna C. Özdemir
Session: Poster session 10
1593P - Factors associated with multiple general practitioner consultations before cancer diagnosis in adolescents and young adults: A cohort study in Australia
Presenter: Jeremy Lewin
Session: Poster session 10